基本信息
浏览量:40
职业迁徙
个人简介
RESEARCH INTERESTS
Our research group focuses on synthetic organic chemistry, with interests in both the development of asymmetric synthetic methodology through the application of new chiral ligands in homogeneous metal-catalysed transformations and in the total synthesis of compounds of biological interest. The preparation of enantiomerically pure compounds is an important area of contemporary synthetic organic chemistry with the market for dosage forms of single enantiomer drugs predicted to rise to $200 billion by 2008. Asymmetric catalysis, one approach for their preparation and the focus of research in both academia and industry, is a technology that is attractive both economically and environmentally. The preparation of new ligands that influence the stereochemistry of reactions occurring at the metal template to which they are complexed is a current focus in our group. We have developed a range of bidentate [N,N] , [N,O] and [P,N] ligands exemplified by structures 1-4, and applied them to the synthetically important asymmetric transformations of the Heck reaction (both intermolecular and intramolecular examples with enantiomeric excesses (ees) up to 99%), allylic substitutions (ees up to 98%), transfer hydrogenation of ketones (up to 96% ee) and rhodium-catalysed hydroboration of alkenes (up to 99.5% ee), Figures 1,2. In addition to the bidentate examples given we have also a significant programme on the development of tridentate ligands, e.g 5-6 (Fig. 3), and these have proven to be particularly efficient in two metal-catalysed processes: (a) allylation and propargylation of aldehydes employing the Nozaki-Hiyama-Kishi reaction (up to 94% ee) and (b) the addition of dialkylzincs to aldehydes (up to 99% ee). We supplement our synthetic effort with mechanistic studies on the catalysts we develop. These studies employ solid-state (X-ray crystallography), solution state (NMR spectroscopy) and computational chemistry in an attempt to understand the origin of the enantio-differentiation in the key step of the catalytic cycle and thus further inform future ligand design. Lipoxins are a group of biologically active mediators derived from arachidonic acid through the action of lipoxygenase enzyme systems. Single-cell types generate lipoxins at nanogram levels during human neutrophil-platelet and eisonophil transcellular biosynthesis of eicosanoids, a class of well known biologically active products. Lipoxins are conjugated tetraene-containing eicosanoids and recent results suggest that they are associated with human disease as they modulate cellular events in several organ systems. Lipoxin A4 (LXA4) (7) and lipoxin B4 (LXB4) (8) are the two major lipoxins, Fig. 4. LXA4 (7) has been identified in bronchoalveolar lavage cells while a defect in LXA4) (7) production is observed with cells from patients with chronic myeloid leukaemia. In light of the biological activity associated with this relatively new class of regulators their total synthesis is actively investigated by a range of workers worldwide. Our work aims to prepare Lipoxin analogues with an active region for biological activity but which resist, or more slowly undergo metabolism and therefore have a longer pharmacological activity. The design feature will also take into account that the analogues should be more lipophilic than the natural lipoxins and therefore are more readily taken up by biological membranes. We also have a long-standing interest in the chemistry and biology of amphetamines and substituted MDMA analogues exemplified by 4-MTA (4-methylthioamphetamine 9).
Our research group focuses on synthetic organic chemistry, with interests in both the development of asymmetric synthetic methodology through the application of new chiral ligands in homogeneous metal-catalysed transformations and in the total synthesis of compounds of biological interest. The preparation of enantiomerically pure compounds is an important area of contemporary synthetic organic chemistry with the market for dosage forms of single enantiomer drugs predicted to rise to $200 billion by 2008. Asymmetric catalysis, one approach for their preparation and the focus of research in both academia and industry, is a technology that is attractive both economically and environmentally. The preparation of new ligands that influence the stereochemistry of reactions occurring at the metal template to which they are complexed is a current focus in our group. We have developed a range of bidentate [N,N] , [N,O] and [P,N] ligands exemplified by structures 1-4, and applied them to the synthetically important asymmetric transformations of the Heck reaction (both intermolecular and intramolecular examples with enantiomeric excesses (ees) up to 99%), allylic substitutions (ees up to 98%), transfer hydrogenation of ketones (up to 96% ee) and rhodium-catalysed hydroboration of alkenes (up to 99.5% ee), Figures 1,2. In addition to the bidentate examples given we have also a significant programme on the development of tridentate ligands, e.g 5-6 (Fig. 3), and these have proven to be particularly efficient in two metal-catalysed processes: (a) allylation and propargylation of aldehydes employing the Nozaki-Hiyama-Kishi reaction (up to 94% ee) and (b) the addition of dialkylzincs to aldehydes (up to 99% ee). We supplement our synthetic effort with mechanistic studies on the catalysts we develop. These studies employ solid-state (X-ray crystallography), solution state (NMR spectroscopy) and computational chemistry in an attempt to understand the origin of the enantio-differentiation in the key step of the catalytic cycle and thus further inform future ligand design. Lipoxins are a group of biologically active mediators derived from arachidonic acid through the action of lipoxygenase enzyme systems. Single-cell types generate lipoxins at nanogram levels during human neutrophil-platelet and eisonophil transcellular biosynthesis of eicosanoids, a class of well known biologically active products. Lipoxins are conjugated tetraene-containing eicosanoids and recent results suggest that they are associated with human disease as they modulate cellular events in several organ systems. Lipoxin A4 (LXA4) (7) and lipoxin B4 (LXB4) (8) are the two major lipoxins, Fig. 4. LXA4 (7) has been identified in bronchoalveolar lavage cells while a defect in LXA4) (7) production is observed with cells from patients with chronic myeloid leukaemia. In light of the biological activity associated with this relatively new class of regulators their total synthesis is actively investigated by a range of workers worldwide. Our work aims to prepare Lipoxin analogues with an active region for biological activity but which resist, or more slowly undergo metabolism and therefore have a longer pharmacological activity. The design feature will also take into account that the analogues should be more lipophilic than the natural lipoxins and therefore are more readily taken up by biological membranes. We also have a long-standing interest in the chemistry and biology of amphetamines and substituted MDMA analogues exemplified by 4-MTA (4-methylthioamphetamine 9).
研究兴趣
论文共 318 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Declan J. Galvin,Patrick J. Guiry
European Journal of Organic Chemistrypp.e202400314, (2024)
Lucy Byrne,Patrick J. Guiry
Moleculesno. 10 (2024): 2233
Chemistry (Weinheim an der Bergstrasse, Germany)pp.e202401738-e202401738, (2024)
European Journal of Organic Chemistry (2024)
ANALYTICAL CHEMISTRY (2024)
EUROPEAN JOURNAL OF ORGANIC CHEMISTRYpp.e202300951, (2024)
Declan Galvin, Eduardo Alberto Aguilar Bejarano,David M. Rogers,Simon Woodward, Ender Özcan,Patrick J. Guiry,Grazziela Figueredo
crossref(2024)
European Journal of Organic Chemistry (2024)
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn